Form 4: Artiva Biotherapeutics Officer's Stock Transaction

Artiva Biotherapeutics' Chief Tech Operations Officer, Christopher Horan, disposed of 1,899 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, Inc. (ARTV), reported a transaction on November 15, 2025.
• 1,899 shares of common stock were disposed of at a price of $3.25 per share.
• This disposition was due to shares being withheld by the company to satisfy income tax obligations related to the vesting of restricted stock unit awards.
• Following this transaction, Christopher Horan beneficially owns 78,183 shares of Artiva Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax withholding related to RSU vesting, which is a neutral event for the company's operational or financial performance.

Positives

• The vesting of restricted stock unit awards indicates active employee compensation and retention mechanisms within the company.

Future Outlook

N/A

Industry Context

This is a standard insider transaction for tax purposes, common across all publicly traded companies when restricted stock units vest, and does not reflect specific industry trends.

Comparison to Industry Standards

• The disposition of shares to cover tax obligations upon RSU vesting is a standard practice for executive compensation across various industries and is consistent with typical corporate governance and compensation structures.

Stakeholder Impact

• Shareholders: No direct impact on company operations or strategy; reflects routine executive compensation.
• Employees: Reinforces standard compensation practices for executives.

Key Dates

Recommendation

This Form 4 filing details a routine disposition of shares by an executive to cover tax obligations upon the vesting of restricted stock units. Such a transaction is a standard part of executive compensation and does not indicate any fundamental change in the company's operations, financial health, or future prospects. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Artiva Biotherapeutics, ARTV, Form 4, insider transaction, stock disposition, restricted stock units, RSU, tax withholding, Christopher Horan